TSX:GTMS

Greenbrook to Voluntarily Delist From Toronto Stock Exchange

Retrieved on: 
Tuesday, February 28, 2023
Mental Health, Health, Neurology, Hospitals, Practice Management, Radiology, Pharmaceutical, Indian stock exchange, TSX, Security (finance)

Effective at the close of markets on March 13, 2023, Greenbrook’s Common Shares will no longer be listed or traded on the TSX.

Key Points: 
  • Effective at the close of markets on March 13, 2023, Greenbrook’s Common Shares will no longer be listed or traded on the TSX.
  • Following delisting from the TSX, the Common Shares will continue to be listed and trade on the NASDAQ under the symbol “GBNH” and Greenbrook’s shareholders can trade their Common Shares through their brokers on NASDAQ.
  • Holders of Common Shares in Canadian brokerage accounts are encouraged to contact their brokers to confirm how to trade their Common Shares on the NASDAQ following the delisting of the Common Shares from the TSX.
  • In accordance with the TSX Company Manual, the TSX does not require shareholder approval of the voluntary delisting of the Common Shares from the TSX, as an acceptable alternative market for the Common Shares exists on NASDAQ.

Greenbrook TMS Draws an Additional US$3.0 Million in Debt Financing

Retrieved on: 
Thursday, February 23, 2023
General Health, Mental Health, Medical Devices, Health, Pharmaceutical, Loan, TSX, Primary Dealer Credit Facility, Conversion, Toronto Stock Exchange, Sale, Line of credit, Regulation, Person, Warrant, Note, London Interbank Bid Rate, Security (finance), Bank

Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (“Greenbrook” or the “Company”), announces today that it has received an aggregate of US$3.0 million in additional debt financing from its existing lender, Madryn Asset Management, LP (“Madryn”), alongside Greybrook Health Inc. (“Greybrook Health”), one of the Company’s existing significant shareholders to manage the company’s current liquidity requirements.

Key Points: 
  • Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (“Greenbrook” or the “Company”), announces today that it has received an aggregate of US$3.0 million in additional debt financing from its existing lender, Madryn Asset Management, LP (“Madryn”), alongside Greybrook Health Inc. (“Greybrook Health”), one of the Company’s existing significant shareholders to manage the company’s current liquidity requirements.
  • The Company is also currently considering additional near-term financing options to address its future liquidity needs.
  • In connection with the New Loan, Madryn was also granted the right to appoint one observer to the board of directors of the Company.
  • As additional consideration for the Greybrook Note Purchase, Greenbrook has agreed to issue 135,870 common share purchase warrants to Greybrook Health (the “Warrants”).

Greenbrook TMS Reports Third Quarter Operational and Financial Results

Retrieved on: 
Tuesday, November 8, 2022
General Health, Mental Health, Medical Devices, Health, Pharmaceutical, Transcranial magnetic stimulation, Phrase, Depression, TMS, FDA, United States Public Health Service, Form 20-F, Eastern Time Zone, Webcast, Annual report, Private Securities Litigation Reform Act, Financial condition report, Investor relations, MDD, Consultant, Mission statement, U.S. Securities and Exchange Commission, Company, Grammatical mood, Conference, Patient, Result, Audit, Pharmaceutical industry, Video game, Risk management

Active TMS Centers represent TMS Centers that have performed billable TMS and other mental health services during the applicable period.

Key Points: 
  • Active TMS Centers represent TMS Centers that have performed billable TMS and other mental health services during the applicable period.
  • TMS Centers-in-development represents TMS Centers that have committed to a space lease agreement and the development process is substantially complete.
  • Represents clinician partners that are involved in the provision of TMS therapy and other mental health services from our TMS Centers.
  • Third Quarter Conference Call Details:
    Bill Leonard, President and Chief Executive Officer, and Erns Loubser, the Chief Financial Officer, will host a conference call at 10:00 a.m. (Eastern Time) on November 9, 2022 to discuss the financial results for the quarter.

Greenbrook TMS Announces Dates for Its Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, October 26, 2022
Mental Health, Health, Patient, Depression, Webcast, Investor relations, TMS, FDA, Transcranial magnetic stimulation, Major depressive disorder, Pharmaceutical industry

For those that plan on accessing the conference call or webcast, please allow ample time prior to the call time.

Key Points: 
  • For those that plan on accessing the conference call or webcast, please allow ample time prior to the call time.
  • Following the live call, a replay will be available on the Investor Relations section of the Companys website, www.greenbrooktms.com/investors/events.htm
    Operating through 191 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (TMS) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States.
  • TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation.
  • Greenbrook has provided more than 900,000 TMS treatments to over 25,000 patients struggling with depression.

Greenbrook TMS Reports Second Quarter Operational and Financial Results

Retrieved on: 
Tuesday, August 2, 2022
General Health, Health, Mental Health, Medical Devices, Result, Transcranial magnetic stimulation, Consultant, Investor relations, U.S. Securities and Exchange Commission, TMS, Success, Eastern Time Zone, Private Securities Litigation Reform Act, Financial condition report, Phrase, Major depressive disorder, Conference, Webcast, Mission statement, FDA, Company, Patient, Annual report, Depression, Form 20-F, High-performance plastics, Audit, Video game, Risk management

Active TMS Centers represent TMS Centers that have performed billable TMS services during the applicable period.

Key Points: 
  • Active TMS Centers represent TMS Centers that have performed billable TMS services during the applicable period.
  • TMS Centers-in-development represents TMS Centers that have committed to a space lease agreement and the development process is substantially complete.
  • Represents clinician partners that are involved in the provision of TMS therapy services from our TMS Centers.
  • Second Quarter Conference Call Details:
    Bill Leonard, President and Chief Executive Officer, and Erns Loubser, the Chief Financial Officer, will host a conference call at 10:00 a.m. (Eastern Time) on August 3, 2022 to discuss the financial results for the quarter.

Greenbrook TMS Announces Dates for Its Second Quarter 2022 Financial Results

Retrieved on: 
Wednesday, July 27, 2022
General Health, Health, Mental Health, Medical Devices, Depression, Webcast, Patient, FDA, Investor relations, TMS, Major depressive disorder, Pharmaceutical industry

For those that plan on accessing the conference call or webcast, please allow ample time prior to the call time.

Key Points: 
  • For those that plan on accessing the conference call or webcast, please allow ample time prior to the call time.
  • TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation.
  • Greenbrook has provided more than 840,000 TMS treatments to over 24,000 patients struggling with depression.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20220727006023/en/

Greenbrook TMS Announces Closing of Success TMS Acquisition and US$75 Million Credit Facility With Madryn Asset Management

Retrieved on: 
Thursday, July 14, 2022
Professional Services, Mental Health, Health, Medical Devices, Neurology, Finance, General Health, Major depressive disorder, Acquisition, Primary Dealer Credit Facility, Madsen v. Women's Health Center, Inc., Patient, Phrase, Toronto Stock Exchange, Depression, U.S. Securities and Exchange Commission, Annual report, Form 20-F, Private Securities Litigation Reform Act, Wainwright Securities Inc. v. Wall Street Transcript Corp., Transcranial magnetic stimulation, TMS, TSX, LLC, NASDAQ, Nasdaq, Company, Growth, Health, Line of credit, LIBOR, COO, Partnership, Indian stock exchange, FDA, Success, Credit, EBITDA, Mental health, Financial services, Bank, Security (finance), Pharmaceutical industry

In addition, Greenbrook announces today that it and its subsidiaries have entered into a credit agreement for a US$75 million secured credit facility (the Credit Facility) with Madryn Asset Management, LP (Madryn) and its affiliated entities.

Key Points: 
  • In addition, Greenbrook announces today that it and its subsidiaries have entered into a credit agreement for a US$75 million secured credit facility (the Credit Facility) with Madryn Asset Management, LP (Madryn) and its affiliated entities.
  • Key Acquisition and Credit Facility highlights:
    The Company believes the Acquisition of Success TMS 47 TMS centers in the states of Florida, Pennsylvania, Illinois, New Jersey, Nevada and Wisconsin is highly complementary to Greenbrooks existing management regions.
  • The Credit Facility provides Greenbrook with a US$55 million term loan, which was funded on closing.
  • Madryn Asset Management is a leading alternative asset management firm that invests in innovative healthcare companies specializing in unique and transformative products, technologies, and services.

Greenbrook TMS Provides an Update on the Success TMS Acquisition

Retrieved on: 
Monday, June 27, 2022
Neurology, Mental Health, Medical Devices, Other Health, Health, Health, FDA, Acquisition, Patient, Transcranial magnetic stimulation, TSX, Growth, Company, Major depressive disorder, Depression, Success, Mission statement, NASDAQ, Oxford, TMS, Intention, Security (finance), Pharmaceutical industry

Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (Greenbrook or the Company), a leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the United States, announced today an update on the status of its previously-announced proposed acquisition (the Acquisition) of Check Five LLC, a Delaware limited liability company (doing business as Success TMS) (Success TMS).

Key Points: 
  • Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (Greenbrook or the Company), a leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the United States, announced today an update on the status of its previously-announced proposed acquisition (the Acquisition) of Check Five LLC, a Delaware limited liability company (doing business as Success TMS) (Success TMS).
  • Greenbrook and Success TMS continue to work diligently towards closing the Acquisition and now expect to complete the Acquisition in early Q3 2022.
  • TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation.
  • Greenbrook has provided more than 840,000 TMS treatments to over 24,000 patients struggling with depression.

Greenbrook TMS Announces Results of Voting at Annual Meeting of Shareholders

Retrieved on: 
Tuesday, June 21, 2022
General Health, Neurology, Mental Health, Medical Devices, Health, Shareholder, The Meeting, Proxy, Transcranial magnetic stimulation, NASDAQ, TSX, Meeting, Holding company

Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (Greenbrook or the Company), a leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the United States, announced today the results of voting at its annual meeting of shareholders held earlier today (the Meeting).

Key Points: 
  • Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (Greenbrook or the Company), a leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the United States, announced today the results of voting at its annual meeting of shareholders held earlier today (the Meeting).
  • Each of the matters voted upon at the Meeting as set out below is described in greater detail in the Notice of Annual Meeting of Shareholders and Management Information Circular of Greenbrook dated May 11, 2022 (the Circular).
  • The total number of common shares represented at the Meeting was 10,711,474, representing approximately 60.17% of Greenbrooks outstanding common shares entitled to be voted.
  • All of the nominees listed in the Management Information Circular of Greenbrook prepared in connection with the Meeting were elected as directors by a resolution passed by a majority of the shareholders represented in person or by proxy at the Meeting, to hold office until the next annual meeting following their election or until their successors are elected or appointed.

Greenbrook TMS to Host Investor Webcast on June 7, 2022

Retrieved on: 
Wednesday, June 1, 2022
Health, Mental Health, Medical Devices, Q&A, Major depressive disorder, Depression, FDA, Transcranial magnetic stimulation, Patient, Webcast, TMS, TSX, Pharmaceutical industry

Greenbrook TMS Inc. (TSX: GTMS) (Greenbrook or the Company) is pleased to announce that it will host a webcast investor presentation on Tuesday, June 7th, 2022, at 2:00 PM ET.

Key Points: 
  • Greenbrook TMS Inc. (TSX: GTMS) (Greenbrook or the Company) is pleased to announce that it will host a webcast investor presentation on Tuesday, June 7th, 2022, at 2:00 PM ET.
  • During the webcast, Bill Leonard, Chief Executive Officer, will conduct a presentation that will cover key areas of Greenbrooks business.
  • To listen to the webcast or to ask questions during the live event, please pre-register at the following link: https://event.webcasts.com/starthere.jsp?ei=1545464&tp_key=65f37425dc .
  • Greenbrook has provided more than 840,000 TMS treatments to over 24,000 patients struggling with depression.